Pyxis Oncology secures $168 million in upsized IPO

9 October 2021
pyxis_oncology_large

Cambridge, Massachusetts, USA-based biotech Pyxis Oncology (Nasdaq: PYXS) made its public debut on Friday after announcing an upside initial public offering IPO), raising $168 million at $16 a share.

Germany’s Bayer (BAYN: DE) and US pharma giant Pfizer (NYSE: PFE) have both invested in the company alongside high-profile biotech investors.

This IPO builds on the momentum the company has gained after exiting stealth mode this year with a one-two punch in March, including a significant in-licensing agreement with Pfizer and a hefty series B financing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology